Hot Flashes
Conditions
Keywords
menopause, fezolinetant, ESN364, vasomotor symptoms
Brief summary
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life. The purpose of this study was to find out how safe it is for these women to take fezolinetant in long term (up to 52 weeks). To do that, the study looked at the number and severity of the adverse events. Those were the side effects that study participants had while they were in the study. The study treatments were fezolinetant 30 milligrams (mg) (1 tablet of fezolinetant and 1 placebo tablet) once a day, fezolinetant 45 mg (2 tablets of fezolinetant) once a day or placebo (2 tablets) once a day. (Placebo was a dummy treatment that looked like medicine but did not have any medicine in it.) Women in this study were picked for 1 of the 3 study treatments by chance alone. The study participants took study treatment for 52 weeks. This study was double-blinded. That means that the study participants and the study doctors did not know who took which of the study treatments (fezolinetant 30 mg, fezolinetant 45 mg or placebo). At weeks 2 and 4 and then once a month, the study participants went to the hospital or clinic for a check-up. They were asked about medications, side effects and how they felt. Other checks included physical exam and vital signs (heart rate, temperature and blood pressure). Blood and urine were collected for laboratory tests. At some study visits, study participants completed questionnaires that were about their quality of life. At the first and last study visits, they had a dual-energy x-ray absorptiometry (DXA for short) test done. To measure bone loss in the hips and spine, DXA created pictures of the inside of these areas with low-dose x-rays. (The dose was approximately one-tenth of the amount of a normal chest x-ray.) Study participants who still had their uterus had 2 more tests done at the first and last study visits. One of the 2 tests was endometrial biopsy. This test involved removing a small amount of tissue from the inside lining of the uterus. The tissue was then checked under a microscope. The other test was transvaginal ultrasound. It used sound waves to create pictures of the organs in the pelvis. The sound waves were transmitted by a probe (transducer), which was placed inside the vagina. Study participants might have had a screening mammogram done at the first and/or last study visit. A mammogram is an x-ray picture of the breasts used to screen for breast cancer. Study participants who did not had this test done in the last 12 months had it done at the first study visit. They had done at the last study visit if they were due for their screening mammogram and their own doctor agreed. The last check-up at the hospital or clinic was at 3 weeks after the last dose of study treatment.
Detailed description
This study consisted of a screening period and a 52 week treatment period. Safety follow up occurred 3 weeks after the last dose of study drug.
Interventions
DRUGfezolinetant
administered orally
DRUGplacebo
administered orally
Sponsors
Astellas Pharma Global Development, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subject has a body mass index ≥ 18 kg/m\^2 and ≤ 38 kg/m\^2. * Subject must be seeking treatment or relief for vasomotor symptoms (VMS) associated with menopause and confirmed as menopausal per 1 of the following criteria at the screening visit: * Spontaneous amenorrhea for ≥ 12 consecutive months * Spontaneous amenorrhea for ≥ 6 months with biochemical criteria of menopause (follicle stimulating hormone \> 40 IU/L), or * Having had bilateral oophorectomy ≥ 6 weeks prior to the screening visit. * Subject is seeking treatment for relief for VMS associated with menopause. * Subject is in good general health as determined on the basis of medical history and general physical examination, including a bimanual clinical pelvic examination and clinical breast examination devoid of relevant clinical findings, performed at the screening visit; hematology and biochemistry parameters; pulse rate and/or blood pressure; and ECG within the reference range for the population studied, or showing no clinically relevant deviations. * Subject has documentation of a normal/negative or no clinically significant mammogram findings (obtained at screening or within the prior 12 months of study enrollment). Appropriate documentation includes a written report or an electronic report indicating normal/negative or no clinically significant mammographic findings. * Subject is willing to undergo a transvaginal ultrasound (TVU) to evaluate the uterus and ovaries at screening and at week 52 end of treatment (EOT). For subjects who are withdrawn from the study prior to completion, a TVU should be collected at the early discontinuation (ED) visit. * Subject is willing to undergo an endometrial biopsy at screening and at week 52 (EOT) or the ED visit for subjects who are withdrawn from the study prior to completion, and any time during the study in the case of uterine bleeding. The endometrial biopsy obtained at screening must be considered evaluable. * Subject has documentation of a normal or not clinically significant Papanicolaou (Pap) test (or equivalent cervical cytology) within the previous 12 months or at screening. * Subject has a negative urine pregnancy test at screening. * Subject has a negative serology panel (i.e., negative hepatitis B surface antigen, negative hepatitis C virus antibody and negative human immunodeficiency virus antibody screens) at screening. * Subject agrees not to participate in another interventional study while participating in the present study.
Exclusion criteria
* Subject uses a prohibited therapy (strong or moderate cytochrome P450 \[CYP\] 1A2 inhibitors, hormone replacement therapy \[HRT\], hormonal contraceptive, any treatment for VMS \[prescription, over the counter or herbal\]) or is not willing to wash out and discontinue such drugs for the full extent of the study. * Subject has a known substance abuse or alcohol addiction within 6 months of screening. * Subject has previous or current history of a malignant tumor, except for basal cell carcinoma. * Subject's systolic blood pressure is ≥ 130 mmHg or diastolic blood pressure is ≥ 80 mmHg based on the average of 2 to 3 readings, on at least 2 different occasions within the screening period. * Subjects who do not meet these criteria may be re-assessed after initiation or review of antihypertensive measures. * Subjects with a medical history of hypertension can be enrolled once they are medically clear (stable and compliant). * Subject has a history of severe allergy, hypersensitivity or intolerance to drugs in general, including the study drug and any of its excipients. * Subject has an unacceptable result from the TVU assessment at screening, i.e., full length of endometrial cavity cannot be visualized or presence of a clinically significant finding. * Subject has an endometrial biopsy confirming presence of disordered proliferative endometrium, endometrial hyperplasia, endometrial cancer, or other clinically significant findings at screening. * Subject has a history within the last 6 months of undiagnosed uterine bleeding. * Subject has a history of seizures or other convulsive disorders. * Subject has a medical condition or chronic disease (including history of neurological \[including cognitive\], hepatic, renal, cardiovascular, gastrointestinal, pulmonary \[e.g., moderate asthma\], endocrine or gynecological disease) or malignancy that could confound interpretation of the study outcome. * Subject has active liver disease, jaundice or elevated liver aminotransferases (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]), elevated total or direct bilirubin, elevated international normalized ratio (INR), or elevated alkaline phosphatase (ALP). Patients with mildly elevated ALT or AST up to 1.5 times the upper limit of normal (ULN) can be enrolled if total and direct bilirubin are normal. Patients with mildly elevated ALP (up to 1.5 x ULN) can be enrolled if cholestatic liver disease is excluded and no cause other than fatty liver is diagnosed. Patients with Gilbert's syndrome with elevated total bilirubin may be enrolled as long as direct bilirubin, hemoglobin and reticulocytes are normal. * Subject has creatinine \> 1.5 x ULN; or estimated glomerular filtration rate using the Modification of Diet in Renal Disease formula ≤ 59 mL/min per 1.73 m\^2 at the screening visit. * Subject has a history of suicide attempt or suicidal behavior within the last 12 months or has suicidal ideation within the last 12 months (a response of yes to questions 4 or 5 on the suicidal ideation portion of the Columbia-Suicide Severity Rating Scale \[C-SSRS\]), or who is at significant risk to commit suicide, as assessed at screening and at the time of visit 2 (randomization). * Subject has previously been enrolled in a clinical trial with fezolinetant. * Subject is participating concurrently in another interventional study or participated in an interventional study within 28 days prior to screening, or received any investigational drug within 28 days or within 5 half-lives prior to screening, whichever is longer. * Subject is unable or unwilling to complete the study procedures. * Subject has any condition which makes the subject unsuitable for study participation. * Subject has had a partial or full hysterectomy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks) | An AE is any untoward medical occurrence in a participant administered a study drug, & which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable & unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. An AE is considered serious if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. A TEAE is defined as an AE observed after starting administration of study drug & 21 days after the last dose of study drug. |
| Number of Participants With Mild, Moderate and Severe TEAE | From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks) | An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. A TEAE is defined as an AE observed after starting administration of the study drug and 21 days after the last dose of study drug. Severity of AE we were classified as Mild: No disruption of normal daily activities; Moderate: Affect normal daily activities; and Severe: Inability to perform daily activities. |
| Percentage of Participants With Endometrial Hyperplasia | Baseline Up to 52 weeks | Endometrial hyperplasia was confirmed from the endometrial biopsy report. |
| Percentage of Participants With Endometrial Cancer | Baseline Up to 52 weeks | Endometrial cancer was confirmed from the endometrial biopsy report. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in BMD at Spine at Week 52 | Baseline and week 52 | Changes in BMD spine was assessed by DXA scan. |
| Change From Baseline in TBS at Spine at Week 52 | Baseline and week 52 | TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture. |
| Change From Baseline in Endometrial Thickness at Week 52 | Baseline and week 52 | Endometrial thicness was obtained from the transvaginal ultrasound. The endometrium was measured in the long axis or sagittal plane. The measurement was of the thickest echogenic area from 1 basal endometrial interface across the endometrial canal to the other basal surface. |
| Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Baseline, week 12, week 24, week 52 and follow-up (week 55) | The C-SSRS assessed the risk for Self-injurious Behavior without Suicidal Intent. Question was asked Has participant engaged in Non-Suicidal Self-Injurious Behavior?. Participants with 'yes' to the question were reported. |
| Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline, week 12, week 24, week 52 and follow-up (week 55) | The C-SSRS assessed the risk for suicidal behavior and suicide ideation. Participants responded as Yes or No 10 items. Suicidal ideation (1. Wish to be dead; 2. Non-specific active suicidal thoughts; 3. Active suicidal ideation with any methods (not plan) without intent to act; 4. Active suicidal ideation with some intent to act, without specific plan; 5. Active suicidal ideation with specific plan and intent; ). Suicidal behaviour (1. Preparatory acts or behavior 2. Aborted attempt 3. Interrupted attempt 4. Actual attempt 5. Completed suicide). Participants with 'Yes' to any one of the above 10 questions for suicidal ideation and behavior were reported. |
| Percentage of Participants With Disordered Proliferative Endometrium | Baseline Up to 52 weeks | Disordered proliferative endometrium was confirmed from the endometrial biopsy report. |
| Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Baseline and week 52 | Changes in BMD hip was assessed by dual-energy X-ray absorptiometry (DXA) scan. |
| Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Baseline and week 52 | TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture. |
Countries
Canada, Czechia, Latvia, Poland, Spain, Ukraine, United Kingdom, United States
Participant flow
Recruitment details
Female participants aged ≥ 40 and ≤ 65 years seeking treatment for vasomotor symptoms (VMS) associated with menopause and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.
Pre-assignment details
Prior to randomization, participants had a screening period during which participants had transvaginal ultrasound, endometrial biopsy, dual-energy X-ray absorptiometry scan.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants received fezolinetant matching placebo (two fezolinetant matching placebo tablets) orally, QD for a of period of 52 Weeks. | 611 |
| Fezolinetant 30 mg Participants received fezolinetant 30 mg (one 30 mg fezolinetant tablet and one placebo tablet) orally, QD for a period of 52 Weeks. | 611 |
| Fezolinetant 45 mg Participants received fezolinetant 45 mg (one 30 mg tablet and one 15 mg tablet) orally, QD for a period of 52 Weeks. | 609 |
| Total | 1,831 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 27 | 34 | 28 |
| Overall Study | Lost to Follow-up | 39 | 30 | 33 |
| Overall Study | Miscellaneous | 14 | 11 | 14 |
| Overall Study | Participant did not receive study drug | 1 | 0 | 0 |
| Overall Study | Protocol Violation | 1 | 6 | 5 |
| Overall Study | Withdrawal by Subject | 119 | 79 | 85 |
Baseline characteristics
| Characteristic | Placebo | Total | Fezolinetant 45 mg | Fezolinetant 30 mg |
|---|---|---|---|---|
| Age, Continuous | 54.8 Years STANDARD_DEVIATION 4.8 | 54.7 Years STANDARD_DEVIATION 4.8 | 54.7 Years STANDARD_DEVIATION 4.8 | 54.7 Years STANDARD_DEVIATION 4.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 133 Participants | 367 Participants | 116 Participants | 118 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 478 Participants | 1462 Participants | 491 Participants | 493 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 2 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 3 Participants | 8 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) Asian | 8 Participants | 29 Participants | 13 Participants | 8 Participants |
| Race (NIH/OMB) Black or African American | 92 Participants | 316 Participants | 110 Participants | 114 Participants |
| Race (NIH/OMB) More than one race | 6 Participants | 16 Participants | 4 Participants | 6 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 2 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) White | 502 Participants | 1460 Participants | 479 Participants | 479 Participants |
| Sex: Female, Male Female | 611 Participants | 1831 Participants | 609 Participants | 611 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Smoking status Current | 117 participants | 349 participants | 116 participants | 116 participants |
| Smoking status Former/Never | 494 participants | 1482 participants | 493 participants | 495 participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 610 | 1 / 611 | 0 / 609 |
| other Total, other adverse events | 90 / 610 | 86 / 611 | 78 / 609 |
| serious Total, serious adverse events | 14 / 610 | 20 / 611 | 23 / 609 |
Outcome results
Primary
Number of Participants With Mild, Moderate and Severe TEAE
An adverse event (AE) is any untoward medical occurrence in a participant administered a study drug, and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product whether or not considered related to the medicinal product. A TEAE is defined as an AE observed after starting administration of the study drug and 21 days after the last dose of study drug. Severity of AE we were classified as Mild: No disruption of normal daily activities; Moderate: Affect normal daily activities; and Severe: Inability to perform daily activities.
Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
Population: SAF population
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Mild, Moderate and Severe TEAE | Moderate | 191 participants |
| Placebo | Number of Participants With Mild, Moderate and Severe TEAE | Mild | 180 participants |
| Placebo | Number of Participants With Mild, Moderate and Severe TEAE | Severe | 20 participants |
| Fezolinetant 30 mg | Number of Participants With Mild, Moderate and Severe TEAE | Moderate | 185 participants |
| Fezolinetant 30 mg | Number of Participants With Mild, Moderate and Severe TEAE | Mild | 215 participants |
| Fezolinetant 30 mg | Number of Participants With Mild, Moderate and Severe TEAE | Severe | 15 participants |
| Fezolinetant 45 mg | Number of Participants With Mild, Moderate and Severe TEAE | Mild | 195 participants |
| Fezolinetant 45 mg | Number of Participants With Mild, Moderate and Severe TEAE | Severe | 23 participants |
| Fezolinetant 45 mg | Number of Participants With Mild, Moderate and Severe TEAE | Moderate | 171 participants |
Primary
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An AE is any untoward medical occurrence in a participant administered a study drug, & which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable & unintended sign, symptom, or disease temporally associated with the use of medicinal product (MP) whether or not considered related to MP. An AE is considered serious if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inpatient hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. A TEAE is defined as an AE observed after starting administration of study drug & 21 days after the last dose of study drug.
Time frame: From first dose of study drug until 21 days after last dose of study drug (Up to 55 weeks)
Population: Safety analysis set (SAF) consisted of all randomized participants who took at least 1 dose of study intervention.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related Serious TEAE | 1 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Death | 0 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE Leading to Death | 0 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Death | 0 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE | 391 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE Leading to Withdrawal of Treatment | 16 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Serious TEAE | 14 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE | 106 participants |
| Placebo | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Withdrawal of Treatment | 26 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Death | 1 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE | 415 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE | 94 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Serious TEAE | 20 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related Serious TEAE | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE Leading to Death | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Withdrawal of Treatment | 34 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE Leading to Withdrawal of Treatment | 16 participants |
| Fezolinetant 30 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Death | 1 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Serious TEAE | 23 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE | 389 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Withdrawal of Treatment | 28 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE | 110 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Death | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | TEAE Leading to Death | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related Serious TEAE | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE Leading to Withdrawal of Treatment | 17 participants |
| Fezolinetant 45 mg | Number of Participants With Treatment Emergent Adverse Events (TEAEs) | Drug-Related TEAE Leading to Death | 0 participants |
Primary
Percentage of Participants With Endometrial Cancer
Endometrial cancer was confirmed from the endometrial biopsy report.
Time frame: Baseline Up to 52 weeks
Population: Endometrial Health Set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Endometrial Cancer | 0 percentage of participants |
| Fezolinetant 30 mg | Percentage of Participants With Endometrial Cancer | 0.5 percentage of participants |
| Fezolinetant 45 mg | Percentage of Participants With Endometrial Cancer | 0 percentage of participants |
Primary
Percentage of Participants With Endometrial Hyperplasia
Endometrial hyperplasia was confirmed from the endometrial biopsy report.
Time frame: Baseline Up to 52 weeks
Population: Endometrial health set (EHS):All randomized participants who received at least 1 dose of study drug, had postbaseline (PB) biopsy done within 30 days after last dose, \& had an acceptable biopsy at baseline (at least 1 endometrial biopsy (EB) with satisfactory tissue \& no read of hyperplasia, disordered proliferative pattern or malignant) \& had a satisfactory EB result after or on day 326 or had a PB final diagnosis of hyperplasia, disordered proliferative pattern or malignant prior to day 326.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Endometrial Hyperplasia | 0 percentage of participants |
| Fezolinetant 30 mg | Percentage of Participants With Endometrial Hyperplasia | 0 percentage of participants |
| Fezolinetant 45 mg | Percentage of Participants With Endometrial Hyperplasia | 0.5 percentage of participants |
Secondary
Change From Baseline in BMD at Spine at Week 52
Changes in BMD spine was assessed by DXA scan.
Time frame: Baseline and week 52
Population: SAF population with available data at specified time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in BMD at Spine at Week 52 | -0.013 g/cm^2 | Standard Deviation 0.035 |
| Fezolinetant 30 mg | Change From Baseline in BMD at Spine at Week 52 | -0.010 g/cm^2 | Standard Deviation 0.049 |
| Fezolinetant 45 mg | Change From Baseline in BMD at Spine at Week 52 | -0.014 g/cm^2 | Standard Deviation 0.034 |
p-value: 0.49795% CI: [-0.005, 0.009]ANCOVA
p-value: 0.87895% CI: [-0.007, 0.006]ANCOVA
Secondary
Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52
Changes in BMD hip was assessed by dual-energy X-ray absorptiometry (DXA) scan.
Time frame: Baseline and week 52
Population: SAF population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Femur) | -0.011 gram per square centimeter (g/cm^2) | Standard Deviation 0.022 |
| Placebo | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Femoral Neck) | -0.010 gram per square centimeter (g/cm^2) | Standard Deviation 0.033 |
| Placebo | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Trochanter) | -0.008 gram per square centimeter (g/cm^2) | Standard Deviation 0.027 |
| Fezolinetant 30 mg | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Femur) | -0.003 gram per square centimeter (g/cm^2) | Standard Deviation 0.041 |
| Fezolinetant 30 mg | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Femoral Neck) | -0.001 gram per square centimeter (g/cm^2) | Standard Deviation 0.044 |
| Fezolinetant 30 mg | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Trochanter) | -0.001 gram per square centimeter (g/cm^2) | Standard Deviation 0.042 |
| Fezolinetant 45 mg | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Femoral Neck) | -0.009 gram per square centimeter (g/cm^2) | Standard Deviation 0.033 |
| Fezolinetant 45 mg | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Trochanter) | -0.004 gram per square centimeter (g/cm^2) | Standard Deviation 0.026 |
| Fezolinetant 45 mg | Change From Baseline in Bone Mineral Density (BMD) at Hip at Week 52 | Hip (Femur) | -0.008 gram per square centimeter (g/cm^2) | Standard Deviation 0.024 |
Comparison: Hip (Femoral Neck)p-value: 0.02995% CI: [0.001, 0.014]ANCOVA
Comparison: Hip (Femoral Neck)p-value: 0.86795% CI: [-0.006, 0.007]ANCOVA
Comparison: Hip (Femur)p-value: 0.02795% CI: [0.001, 0.012]ANCOVA
Comparison: Hip (Femur)p-value: 0.4195% CI: [-0.003, 0.008]ANCOVA
Comparison: Hip (Trochanter)p-value: 0.08795% CI: [-0.001, 0.011]ANCOVA
Comparison: Hip (Trochanter)p-value: 0.25995% CI: [-0.002, 0.009]ANCOVA
Secondary
Change From Baseline in Endometrial Thickness at Week 52
Endometrial thicness was obtained from the transvaginal ultrasound. The endometrium was measured in the long axis or sagittal plane. The measurement was of the thickest echogenic area from 1 basal endometrial interface across the endometrial canal to the other basal surface.
Time frame: Baseline and week 52
Population: SAF population with available data at specified time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Endometrial Thickness at Week 52 | -0.17 millimeter (mm) | Standard Deviation 2.35 |
| Fezolinetant 30 mg | Change From Baseline in Endometrial Thickness at Week 52 | -0.15 millimeter (mm) | Standard Deviation 1.97 |
| Fezolinetant 45 mg | Change From Baseline in Endometrial Thickness at Week 52 | -0.28 millimeter (mm) | Standard Deviation 2.3 |
Comparison: LSMeans (LSM), standard errors (SE), confidence intervals (CI)p-value: 0.060495% CI: [-0.36, 0.21]ANCOVA
p-value: 0.23995% CI: [-0.45, 0.11]ANCOVA
Secondary
Change From Baseline in TBS at Spine at Week 52
TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.
Time frame: Baseline and week 52
Population: SAF population with available data at specified time point.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in TBS at Spine at Week 52 | -0.117 T-Score (Index) | Standard Deviation 0.296 |
| Fezolinetant 30 mg | Change From Baseline in TBS at Spine at Week 52 | -0.084 T-Score (Index) | Standard Deviation 0.025 |
| Fezolinetant 45 mg | Change From Baseline in TBS at Spine at Week 52 | -0.119 T-Score (Index) | Standard Deviation 0.298 |
p-value: 0.52795% CI: [-0.042, 0.082]ANCOVA
p-value: 0.87295% CI: [-0.066, 0.056]ANCOVA
Secondary
Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52
TBS was a bone texture assessment that serves as a substitute for bone microarchitecture and predicts fracture risk independent of BMD and clinical risk factors. The DXA imaging was processed and analyzed as it would normally be and then evaluated using an automated algorithm to determine the TBS. T-score ≥1.350 was considered to be normal; T-score between 1.200 and 1.350 is considered to be consistent with partially degraded microarchitecture; and T-score ≤1.200 defines degraded microarchitecture.
Time frame: Baseline and week 52
Population: SAF population with available data at specified time point.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Femur) | -0.085 T-Score (Index) | Standard Deviation 0.192 |
| Placebo | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Femoral Neck) | -0.078 T-Score (Index) | Standard Deviation 0.246 |
| Placebo | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Trochanter) | -0.071 T-Score (Index) | Standard Deviation 0.255 |
| Fezolinetant 30 mg | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Femur) | -0.024 T-Score (Index) | Standard Deviation 0.354 |
| Fezolinetant 30 mg | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Femoral Neck) | -0.011 T-Score (Index) | Standard Deviation 0.372 |
| Fezolinetant 30 mg | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Trochanter) | -0.009 T-Score (Index) | Standard Deviation 0.426 |
| Fezolinetant 45 mg | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Femoral Neck) | -0.073 T-Score (Index) | Standard Deviation 0.265 |
| Fezolinetant 45 mg | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Trochanter) | -0.036 T-Score (Index) | Standard Deviation 0.246 |
| Fezolinetant 45 mg | Change From Baseline in Trabecular Bone Score (TBS) at Hip at Week 52 | Hip (Femur) | -0.063 T-Score (Index) | Standard Deviation 0.192 |
Comparison: Hip (Femoral Neck)p-value: 0.07995% CI: [-0.006, 0.102]ANCOVA
Comparison: Hip (Femoral Neck)p-value: 0.9895% CI: [-0.052, 0.053]ANCOVA
Comparison: Hip (Femur)p-value: 0.04295% CI: [0.002, 0.094]ANCOVA
Comparison: Hip (Femur)p-value: 0.38695% CI: [-0.025, 0.065]ANCOVA
Comparison: Hip (Trochanter)p-value: 0.15695% CI: [-0.016, 0.099]ANCOVA
Comparison: Hip (Trochanter)p-value: 0.32895% CI: [-0.028, 0.084]ANCOVA
Secondary
Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS
The C-SSRS assessed the risk for Self-injurious Behavior without Suicidal Intent. Question was asked Has participant engaged in Non-Suicidal Self-Injurious Behavior?. Participants with 'yes' to the question were reported.
Time frame: Baseline, week 12, week 24, week 52 and follow-up (week 55)
Population: SAF population with available data at specified time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 52 | 0 participants |
| Placebo | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 24 | 0 participants |
| Placebo | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Baseline | 0 participants |
| Placebo | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 12 | 1 participants |
| Placebo | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Follow-up (Week 55) | 1 participants |
| Fezolinetant 30 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 24 | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Baseline | 1 participants |
| Fezolinetant 30 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 12 | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 52 | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Follow-up (Week 55) | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Follow-up (Week 55) | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 52 | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Baseline | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 24 | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Self-injurious Behavior Without Suicidal Intent as Assessed by C-SSRS | Week 12 | 0 participants |
Secondary
Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS assessed the risk for suicidal behavior and suicide ideation. Participants responded as Yes or No 10 items. Suicidal ideation (1. Wish to be dead; 2. Non-specific active suicidal thoughts; 3. Active suicidal ideation with any methods (not plan) without intent to act; 4. Active suicidal ideation with some intent to act, without specific plan; 5. Active suicidal ideation with specific plan and intent; ). Suicidal behaviour (1. Preparatory acts or behavior 2. Aborted attempt 3. Interrupted attempt 4. Actual attempt 5. Completed suicide). Participants with 'Yes' to any one of the above 10 questions for suicidal ideation and behavior were reported.
Time frame: Baseline, week 12, week 24, week 52 and follow-up (week 55)
Population: SAF population with available data at specified time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 52 | 1 participants |
| Placebo | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 24 | 1 participants |
| Placebo | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline | 2 participants |
| Placebo | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 12 | 0 participants |
| Placebo | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Follow-up (Week 55) | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 24 | 1 participants |
| Fezolinetant 30 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline | 2 participants |
| Fezolinetant 30 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 12 | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 52 | 0 participants |
| Fezolinetant 30 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Follow-up (Week 55) | 1 participants |
| Fezolinetant 45 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Follow-up (Week 55) | 2 participants |
| Fezolinetant 45 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 52 | 0 participants |
| Fezolinetant 45 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Baseline | 4 participants |
| Fezolinetant 45 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 24 | 2 participants |
| Fezolinetant 45 mg | Number of Participants With Suicidal Ideation and/or Behaviour as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS) | Week 12 | 1 participants |
Secondary
Percentage of Participants With Disordered Proliferative Endometrium
Disordered proliferative endometrium was confirmed from the endometrial biopsy report.
Time frame: Baseline Up to 52 weeks
Population: Endometrial Health Set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants With Disordered Proliferative Endometrium | 2.2 percentage of participants |
| Fezolinetant 30 mg | Percentage of Participants With Disordered Proliferative Endometrium | 1.4 percentage of participants |
| Fezolinetant 45 mg | Percentage of Participants With Disordered Proliferative Endometrium | 0 percentage of participants |